GABAA receptor positive allosteric modulators

Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Retrieved on: 
Wednesday, February 10, 2021

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company is conducting a Phase 3 trial in status epilepticus.

Melt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate

Retrieved on: 
Tuesday, February 9, 2021

We are pleased with the results of our Phase 1 MELT study, which marks another important milestone for the Company, said Greg Madison, CEO of Melt Pharmaceuticals.

Key Points: 
  • We are pleased with the results of our Phase 1 MELT study, which marks another important milestone for the Company, said Greg Madison, CEO of Melt Pharmaceuticals.
  • MELT is a patented combination of midazolam and ketamine in a rapidly dissolving, sublingual tablet to provide sedation and analgesia for patients undergoing cataract surgery.
  • This needle-free and opioid-free approach seeks to replace the current practice of IV-delivered sedation medication for patients.
  • Melts core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States.

US General Anesthesia Drugs Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 4, 2021

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.

Key Points: 
  • Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
  • Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
  • General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
  • Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.

US General Anesthesia Drugs Market worth $2.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, February 4, 2021

Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.

Key Points: 
  • Based on the route of administration, US general anesthesia drugs market is categorized into inhalational anesthesia drugs and intravenous anesthesia drugs.
  • Similarly, intravenous anesthesia drugs are further categorized into propofol, benzodiazepines, ketamine, methohexital sodium and others intravenous general anesthesia drugs.
  • General intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
  • Based on end user, the US general anesthesia drugs market has been segmented into hospitals and ambulatory surgery centers.

Cymbiotika Combats LDL Cholesterol with New Red Yeast Rice

Retrieved on: 
Tuesday, February 2, 2021

Cymbiotika , a leading nutritional supplement brand known for creating pure, clinically backed supplements, has launched Red Yeast Rice.

Key Points: 
  • Cymbiotika , a leading nutritional supplement brand known for creating pure, clinically backed supplements, has launched Red Yeast Rice.
  • In the United states, Red Yeast Rice has been used as a natural alternative to statin therapy in treating people with mild to moderate hypercholesterolemia by significantly lowering LDL (bad) cholesterol levels, as well as total cholesterol.
  • Cymbiotika Red Yeast Rice has zero synthetic ingredients and is gluten-free, vegan, keto, and sugar-free.
  • It is also available in the Cholesterol and Healthy Heart Bundle (Red Yeast Rice, D3K2, Omega and Adrenal Super Tonic).

FOLX Health Raises $25M Series A, Launches Product and Clinical Offerings for the LGBTQIA+ Community

Retrieved on: 
Tuesday, February 2, 2021

FOLX Health is also announcing the availability of its Hormone Replacement Therapy (HRT: testosterone or estrogen) with monthly plans starting at $59 a month.

Key Points: 
  • FOLX Health is also announcing the availability of its Hormone Replacement Therapy (HRT: testosterone or estrogen) with monthly plans starting at $59 a month.
  • Upon launch, FOLX Health is available in: CA, CT, DE, FL, IL, MA, NC, NY, TX, VA, WA.
  • As part of its mission to demystify health care and build a Queer and Trans centric health service for the LGBTQIA+ community, FOLX Health is also launching the FOLX Library .
  • For more information on FOLX Health, please visit: https://folxhealth.com
    Launched in December 2020, FOLX Health is an LGBTQIA+ healthcare service provider built to serve the community's specific needs.

Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination

Retrieved on: 
Monday, February 1, 2021

According to the CDC, approximately 28% of Americans over forty years of age are prescribed a statin for hypercholesterolemia.

Key Points: 
  • According to the CDC, approximately 28% of Americans over forty years of age are prescribed a statin for hypercholesterolemia.
  • In US clinical practices, roughly 45% of patients discontinue statin use after 6 months use due to adverse effects.
  • Findings suggest that cannabinoids such as Cannabidiol in combination with statins decrease the adverse effects of statin drugs while increasing efficacy in treating cardiovascular disease such as hypercholesterolemia.
  • We are extremely pleased to have been granted the first patent for our portfolio of cannabinoid-statin combination therapies.

Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome

Retrieved on: 
Monday, February 1, 2021

Patients with Dravet syndrome experience severe and often prolonged seizures that are highly resistant to existing anti-convulsant medications.

Key Points: 
  • Patients with Dravet syndrome experience severe and often prolonged seizures that are highly resistant to existing anti-convulsant medications.
  • FINTEPLA will be available in Germany starting on 1 February 2021 under a controlled access program requested by the European Medicines Agency.
  • In Germany, physicians will register for an identification number before being able to prescribe FINTEPLA via the following website: www.fenfluramin-wichtige-infos.de/verschreiber .
  • These statements include the potential that fenfluramine oral solution will be an important new treatment option for Dravet syndrome patients and Zogenixs plans to commercialize fenfluramine in Europe.

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*

Retrieved on: 
Friday, January 29, 2021

Cenobamate has been shown to significantly improve seizure control for focal-onset seizures in adult patients and this positive CHMP opinion means that patients may soon have a new treatment option, he added.

Key Points: 
  • Cenobamate has been shown to significantly improve seizure control for focal-onset seizures in adult patients and this positive CHMP opinion means that patients may soon have a new treatment option, he added.
  • Positive CHMP opinion of cenobamate represents an important milestone for Angelini Pharma and for patients.
  • The CHMP positive opinion was based on three trials involving over 1,900 patients.
  • Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures NCT03678753.

Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX

Retrieved on: 
Thursday, January 28, 2021

There is a huge opportunity for Marius to address these issues and drastically alter the testosterone therapy landscape.

Key Points: 
  • There is a huge opportunity for Marius to address these issues and drastically alter the testosterone therapy landscape.
  • Shalin Shah will also step into the role of co-CEO from chief financial officer and executive vice president of strategy for Marius.
  • If approved by the FDA, KYZATREX has the potential to become the new standard of care for treating patients with hypogonadism.
  • Marius is a specialty pharmaceutical company focusing on treating conditions that are primarily associated with hypogonadism, commonly referred to as testosterone deficiency.